PDK4 and cancer: Furthermore, our results suggested that EGFR degradation was attributed to Erk inactivation-induced PDK4 up-regulation to decrease ATP and activate AMPK, providing the clue that AMPK activation might enhance anti-cancer of dasatinib through targeting EGFR.